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ABSTRACT An important component of triple-drug anti-
AIDS therapy is 2*,3*-dideoxy-3*-thiacytidine (3TC, lamivu-
dine). Single mutations at residue 184 of the reverse tran-
scriptase (RT) in HIV cause high-level resistance to 3TC and
contribute to the failure of anti-AIDS combination therapy.
We have determined crystal structures of the 3TC-resistant
mutant HIV-1 RT (M184I) in both the presence and absence
of a DNAyDNA template-primer. In the absence of a DNA
substrate, the wild-type and mutant structures are very
similar. However, comparison of crystal structures of M184I
mutant and wild-type HIV-1 RT with and without DNA reveals
repositioning of the template-primer in the M184IyDNA bi-
nary complex and other smaller changes in residues in the
dNTP-binding site. On the basis of these structural results, we
developed a model that explains the ability of the 3TC-
resistant mutant M184I to incorporate dNTPs but not the
nucleotide analog 3TCTP. In this model, steric hindrance is
expected for NRTIs with b- or L- ring configurations, as with
the enantiomer of 3TC that is used in therapy. Steric conflict
between the oxathiolane ring of 3TCTP and the side chain of
b-branched amino acids (Val, Ile, Thr) at position 184 per-
turbs inhibitor binding, leading to a reduction in incorpora-
tion of the analog. The model can also explain the 3TC
resistance of analogous hepatitis B polymerase mutants.
Repositioning of the template-primer as observed in the
binary complex (M184IyDNA) may also occur in the catalytic
ternary complex (M184IyDNAy3TCTP) and contribute to
3TC resistance by interfering with the formation of a cata-
lytically competent closed complex.
The introduction of combination drug therapies for the treat-
ment of AIDS has resulted in a dramatic decrease in AIDS-
related deaths in the United States. One of the standard
components in these treatments is 29,39-dideoxy-39-thiacyti-
dine (3TC), a second-generation nucleoside analog reverse
transcriptase inhibitor (NRTI) that has a substantially im-
proved pharmacological profile compared with AZT and the
dideoxynucleotide inhibitors (1, 2). Like other NRTIs, the
triphosphate of 3TC (3TCTP) inhibits RT by causing termi-
nation of the growing DNA chain. In lieu of the ribose ring of
canonical nucleosides, 3TC has a b-L-oxathiolane ring system
(Fig. 1) (3, 4). Although not as efficient an inhibitor of HIV-1
RT as some of the other NRTIs (mM vs. nM Ki), 3TC has much
lower toxicity, apparently because it is not a good substrate for
mitochondrial DNA polymerases (2, 3).
3TC is also a potent inhibitor of hepadnavirus polymerases
(1, 5). Despite the availability of an effective vaccine, about 5%
of the world’s population is chronically infected with hepatitis
B virus (HBV) (6). In Phase II clinical trials (7), 3TC treatment
was shown to reduce HBV viral loads dramatically. As with
HIV-1, however, viral resistance to 3TC develops in cell
cultures and in clinical studies (8, 9). Clinical treatment of
HBV infection by using 3TC has recently been approved.
Structural Background. A number of crystal structures of
HIV-1 RT have been determined, including structures of
unliganded HIV-1 RT (10–12), HIV-1 RT complexed with a
19:18 double-stranded DNA template-primer and the Fab
fragment of a monoclonal antibody (13, 14), and HIV-1 RT
complexed with a 25:21 double-stranded DNA template-
primer and dTTP (15). HIV-1 RT is a heterodimer, composed
of a larger 560-residue chain (p66) and a second smaller
subunit (p51) that contains the N-terminal 440 residues of the
p66 subunit. Although both subunits contain the fingers, palm,
thumb, and connection subdomains, only p66 has a polymerase
active site and a DNA-binding cleft formed by the p66 fingers,
palm, and thumb subdomains (16). In HIV-1 RT, M184 is the
second residue of the highly conserved YXDD (Tyr-X-Asp-
Asp) motif, which contains two of the three essential aspartic
acids that define the polymerase active site (17, 18). In all
HIV-1 RT structures, the YXDD motif makes an unusual type
II9 turn that positions the side chains of the four consecutive
amino acids (YXDD) on the surface of the p66 palm subdo-
main, allowing for interactions with template-primer, dNTP,
and metal cofactors. Most retroviral RTs (including HIV-1
RT) and the HBV polymerase contain a methionine residue as
amino acid X; in Moloney murine leukemia virus (MuLV) RT
the motif is YVDD (19). In HBV polymerase, residue X is
M552. Nonretroviral RTs contain the alternative motifs
YIDD, YLDD, and YADD (19–21). The dNTP-binding site in
HIV-1 RT is composed of both protein and nucleic acid.
Among the residues that contribute, either directly or indi-
rectly, to the formation of the dNTP-binding site are Y115,
F116, F160, Q151, and L74 of the p66 subunit (15, 22–27).
Resistance to 3TC. Initially, resistance to 3TC is associated
with the substitution of isoleucine for methionine at position
184 of HIV-1 RT, which results from a single base change
(ATG3 ATA). The M184I variant is rapidly replaced by the
variant M184V during 3TC therapy (28–35). Similar mutations
at the equivalent position in HBV polymerase and in simian
immunodeficiency virus and feline immunodeficiency virus
RTs confer resistance to 3TC, suggesting a common mecha-
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nism of resistance to b-L-nucleoside inhibitors (36–39). In
HBV polymerase, 3TC resistance is associated either with a
single mutation of methionine to isoleucine at position 552 in
the YMDD motif or with two mutations that occur concom-
itantly (M552VyL528M) (8).
Despite the plethora of biochemical and clinical data on
NRTI-resistant mutants of HIV-1 RT, the structural details
that underlie NRTI resistance are not well understood. On the
basis of a combination of biochemical, crystallographic, and
molecular modeling experiments, we have proposed that al-
teration of positioning of the nucleic acid template-primer can
play an important role in NRTI resistance (22, 23, 40, 41). We
now know from the structure of RTyDNA complexed with
dTTP (RTyDNAydTTP) (15) that the ternary complex is a
closed structure with the fingers folded down toward the
dNTP-binding site and the extended template overhang bent
away from the DNA duplex. Many of the NRTI-resistance
mutations are closer to the bound dNTP than were previously
predicted. Nevertheless, repositioning of template-primer is
still likely to affect dNTP and NRTI binding by distorting the
dNTP-binding pocket.
In wild-type RT, M184 contacts both the 39 end of the
primer and the dNTP. Presteady and steady-state kinetic
studies with the 3TC-resistant M184V mutant have shown that
there is a relatively small change in the ability of the mutant
enzyme to bind dNTP (42, 43) and 3TCTP (43) and that the
turnover rate of 3TC by M184V HIV-1 RT is substantially
decreased relative to the wild-type enzyme. However, another
kinetic study with 29-39-dideoxy-39-thia-5-f luorocytidine
(FTC) (42), the 5-fluoro analog of 3TC, reported the opposite
effect: the M184V mutation affects binding of FTCTP (’18-
fold increase in Kd) rather than the turnover rate of FTC
incorporation (unchanged kp). Although the relative resis-
tance of RT to 3TC and to FTC is significantly different
(KiM184V RTyKiWT RT is 50 for 3TC and .500 for FTC), the
structural similarity of the two inhibitors suggests that these
two inhibitors should have a common mechanism of drug
resistance. On the basis of the crystal structure of wild-type
RTyDNAydNTP (15), Huang et al. have suggested that the
side chain of either a valine or an isoleucine at position 184
would interfere with 3TCTP binding. However, in the absence
of structures for 3TC-resistant RTs in complexes with a
template-primer and 3TCTP, the structural details of 3TC
resistance have not yet been elucidated.
In this study, we compare the crystal structures of the
wild-type RTyDNA complex with an HIV-1 RT mutant
(M184I) in the presence of an identical oligonucleotide sub-
strate (3.5-Å resolution). The structures of unliganded wild-
type and M184I RTs (2.85-Å resolution) were also compared.
The structural information was used to develop a model that
explains the ability of 3TC-resistant mutant M184I to incor-
porate dNTPs but not the nucleotide analog 3TCTP. In this
model, steric conflict between the oxathiolane ring of 3TCTP
and the side chain of b-branched amino acids (Val, Ile, Thr)
at position 184 perturbs the stereochemistry of inhibitor
binding, leading to a reduced turnover rate. The repositioning
of the template-primer seen in the binary complexes may also
occur in the catalytic complex and contribute to 3TC resis-
tance. A combination of these factors could interfere with the
formation of a catalytically competent closed complex.
MATERIALS AND METHODS
Purification and crystallization of M184I RTyDNAyFab was
done as described previously for the corresponding wild-type
complex (13, 14). Specifically, purified HIV-1 RT was mixed
with Fab at 1:0.8 mass ratio (total protein concentration: 25
mgyml) and 0.2 mM 19:18 DNA (19-mer template: 39-
AGGGACAAGCCCGCGGTA-59, template overhang in
bold). Hanging drops were prepared by mixing equal volumes
of the complex and crystallization solutions (100 mM cacody-
late, pH 5.6y29–31% saturated ammonium sulfate) at 4°C. For
unliganded M184I RT, the crystallization solution contained
50 mM BiszTris, 100 mM (NH4)2SO4, 10% glycerol, and 9%
polyethylene glycol 8000, pH 6.8 (16). Diffraction datasets
were collected at the Cornell High Energy Synchrotron Source
(CHESS) F1 beam line and at the Brookhaven National Light
Source X-25 beam line (Table 1).
Structure Determination. The structures of cooled and
frozen M184I RTyDNAyFab complexes were solved by mo-
lecular replacement with wild-type HIV-1 RTyDNAyFab as a
starting model (13, 14). To improve the phase quality and
reduce model bias, at the early stages of structure determina-
tion we used the program RAVE and the multiple crystal
averaging program DMMULTI to average the electron density
maps of the frozen and cooled datasets at 3.6-Å resolution. To
further reduce model bias, we calculated maps with the DNA
and the polymerase active site omitted from the model.
Rounds of model building were guided by using both normal
and averaged omit maps. The DNA position was clearly
indicated in both difference Fourier (Fobs2Fcalc) and the
averaged electron density 2Fobs2Fcalc maps computed for
M184I RTyDNAyFab complexes. Both maps were calculated
by using phases derived from only the protein model, before
FIG. 1. Chemical structures of deoxythymidine and various NRTIs,
with aligned C19 and C49 atoms of the nucleoside rings. Such alignment
highlights the unique direction (arrows pointing down) of the b-L-
nucleosides ring, projecting in the opposite direction from the other
nucleoside and nucleoside analog inhibitors (arrows pointing up).
Table 1. Summary of crystallographic data and
refinement statistics
M184I RTyDNAyFab
M184I RT,
unliganded
Space group P3212 P3212 C2
Temperature, °C 210 2165 2165
Resolution range, Å 4023.5 4023.6 4022.85
Cell parameters, a, Å 169.2 167.4 238.6
b, Å 169.2 167.4 72.7
c, Å 221.9 219.7 95.3
b, ° 90 90 105.6
Completeness, % 91.5 (83) 84.0 (82) 94.9 (88)
(highest shell)
Rmerge, % 11.8 11.3 9.0
Refinement statistics
Resolution range, Å 1023.5 822.85
No. of reflections 39,033 31,200
R-factor 26.2 25.9
Free R-factor 33.8 34.6
No. of protein atoms 11,720 7,700
Luzzati error, Å 0.53 0.48
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any information about bound DNA was included either in the
structure refinements or in the map calculations. Stereochemi-
cally restrained structure refinement was performed by using
the program XPLOR (44), varying positional and individual
isotropic thermal parameters by using a protocol similar to the
one used for the corresponding wild-type structure refinement
(13). The unliganded M184I structure was solved by using
molecular replacement with the unliganded wild-type HIV-1
RT structure (12) as the starting model, with the mutated and
the surrounding residues omitted.
RESULTS AND DISCUSSION
Comparison of Structures. Overall the structures of wild-
type HIV-1 RT and the M184I mutant are quite similar either
in the presence or in the absence of double-stranded DNA
substrate. Specifically, when the unliganded structures of
wild-type and mutant HIV-1 RT were compared by superpo-
sition of the Ca atoms of amino acid residues 107 to 115 and
151 to 215 of the p66 palm subdomain, the rms deviation was
0.3 Å.
A similar superposition (using the same residue ranges) of
the polymerase active sites of the wild-type and mutant RT
complexes with DNA gave an rms deviation of 0.4 Å. There is,
however, a substantial shift in the position of the last few
nucleotides of the primer strand near the polymerase active
site (Fig. 2). The largest shift in the primer strand is at the
39-terminal nucleotide, which is adjacent to the side chain of
residue 184 of the p66 subunit, resulting in a displacement of
the 39-OH by approximately 1.5 Å. The hydrogen-bonding
interaction between the O2 atom of the penultimate nucleo-
tide of the primer strand and the side chain of Y183 (Fig. 3)
is stronger in the M184I complex [the distance between these
groups decreases from 3.5 Å in the wild-type RTyDNA
complex (13) to 2.5 Å in the M184I RTyDNA complex
(Fig. 3)].
Smaller changes were observed for complementary nucle-
otides near the 59-end of the template strand (Fig. 3). We also
observed changes in the position of the unpaired 59-nucleotide
of the template strand (Fig. 3); however, this nucleotide is still
stacked over the terminal base pair of the template-primer in
a position (relative to the nucleic acid) reminiscent of the
arrangement seen in the wild-type RTyDNA complex.
Despite the differences in template-primer position when
the wild-type HIV-1 RT is compared with the M184I mutant,
the effect of DNA binding on the YXDD motif was similar for
the wild-type and mutant enzymes. Specifically, the ‘‘punched-
down’’ conformation of the YXDD motif at the tip of b9-b10
that has been previously reported for wild-type HIV-1 RT in
the presence of DNA substrate (14) was also observed for the
mutant enzyme. The side chain of I184 of the p66 subunit is
well ordered in the M184I RTyDNA complex. However, in the
unliganded M184I structure the I184 residue in the p66 subunit
is disordered. The electron density for I184 in the p51 subunit
is well defined in both apo and DNA-bound M184I RT
structures.
Changes were also observed in residues proximal to the
dNTP-binding site in the M184I RTyDNA complex (Fig. 3).
Five of these residues are close to the template-primer (D110,
D185, Q151, Y115, and L74). The displacements range up to
2.4 Å when the p66 subunits of the mutant and wild-type
RTyDNA complexes are compared (e.g., 1.1 Å for Od1 of
D110; 2.4 Å for Og of D185; 1.2 Å for Oh of Y115; 1.1 Å for
Ca of Q151; and 1.8 Å for Cb of L74). The side chains of D185
and D110 follow the displaced primer terminus of the M184I
RTyDNA complex (Fig. 3) and the hydrogen bond between
Od1 of D185, and 39-OH of the primer terminus becomes even
stronger in the mutant RTyDNA complex (decrease in dis-
tance from 3.3 Å to 2.7 Å). However, the hydrogen bond
between Od2 of D185 and the main-chain carbonyl of V111 is
lost (increase in distance from 2.7 to 4.3 Å).
The b12–b13 connecting loop has been previously termed
the ‘‘primer grip’’ because it helps position the primer strand
at the active site (13, 23, 45–47). A comparison of the
DNA-bound structures shows changes (’1 Å) in the positions
of the side chains of residues that are close to the primer DNA
strand. These residues include W229 and Y232 of the primer
grip, and W266 of the p66 thumb. These changes are associated
with the primer repositioning: they are not observed when the
unliganded structures are compared.
Resistance to b-L-Nucleosides, Including 3TC, Involves
Steric Hindrance. Using the M184I RTyDNA and wild-type
RTyDNA crystal structures, we have modeled the interactions
of dCTP and 3TCTP at the active site of the M184I enzyme
(Fig. 4), assuming similar binding of the triphosphate moieties
and similar base-pairing interactions of the incoming inhibitors
with a modeled template overhang. The predicted position of
the nucleotide with respect to the active site YIDD motif in this
model is strongly supported by the structure of the polymerase
active site in the recently reported ternary HIV-1 RTyDNAy
dTTP complex (15). The 3TCTP and dCTP nucleoside ring
configurations are enantiomeric (Fig. 1), so that alignment of
the triphosphates and bases would cause the nucleoside ring of
the b-L-inhibitor to project 1.5–2.0 Å further toward residue
184 than would the ribose ring of dCTP (Fig. 4). The most
significant difference between the interactions of wild-type
HIV-1 RT and the M184I mutant with ribose and b-L-
oxathiolane nucleoside inhibitors is a very close contact pre-
dicted between the Cg2 methyl of Ile and the protruding
oxathiolane ring (Fig. 4). This unfavorably close contact (2.5 Å
in M184I vs. 3.9 Å in wild type) would result in severe steric
hindrance. The steric conflict would be effectively enforced by
the conformational restriction of the b-branched I184 side
chain. I184 is constrained both by interactions with the Y115
and Y183 side chains and by interactions with nearby main-
chain atoms of the type II9 b turn in an already crowded
polymerase active site (Figs. 2 and 3). In contrast to I184, the
wild-type M184 side chain not only lacks a b branch but also
has greater conformational f lexibility, permitting 3TCTP to
bind without significant steric conflict. The same mechanism
also explains why the only other reported 3TC-resistance
mutations are M184V and M184T: valine and threonine are
FIG. 2. Superposition of the polymerase active sites of wild-type
HIV-1 RTyDNAyFab and M184I HIV-1 RTyDNAyFab. The wild-
type RT complex is shown in white, the mutant RT complex in cyan.
The wild-type and M184I RT structures were superimposed on the
basis of the core of the p66 palm subdomains (residues 107 to 112 and
151 to 215 of their corresponding p66 subunits).
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the only other amino acids with b-branched methyl substitu-
ents (35, 48).
In support of this concept, an analogous complex of M184V
RT with DNA reveals that the V184 side chain has its b-methyl
group in a similar position (unpublished results). In addition,
as predicted by this model, the M184A HIV-1 RT mutant,
which lacks a b-methyl substituent at the 184 position, does not
discriminate between b-L- and b-D-ring systems (42). RT
resistance to 3TC expressed as the KiyKm ratio for 3TCTP to
dTTP is similar for M184A and wild-type HIV-1 RT (42).
Steric hindrance between 3TCTP (or FTCTP) and Ile-184
of M184I RT would not necessarily block the binding of
3TCTP (or FTCTP)—it could shift the binding position of
these inhibitors. If the character rather than the extent of
binding of b-L-oxathiolane inhibitors is decreased, it is also
possible that such changes will affect the interactions that
cause the fingers to fold down in the ternary catalytic complex
(15). Hence, resistance to 3TC may be the result of perturbed
stereochemistry of 3TCTP binding in the M184I RTyDNAy
3TCTP complex, potentially leading to an abortive transition
state. The nucleoside ring geometry of canonical dNTPs
minimizes the steric clash with the b-branched side chain of
3TC-resistant RTs apparently resulting in only small changes
in dNTP binding. In the absence of a b-branched chain at the
184 position, wild-type RT is able to incorporate nucleotides
with unfavorable stereochemistry such as 3TCTP, albeit less
efficiently than normal nucleotide substrates.
In addition to explaining RT resistance to b-L-oxathiolane
nucleoside inhibitors (3TC and FTC), this model can be
generalized to explain RT resistance to all nucleoside inhibi-
tors with b-L-stereochemistry. In fact, the model correctly
predicts that mutants with b-branched amino acids at position
184 have less resistance to b-L-ddCTP than to 3TCTP (42, 49,
50). This is because b-L-ddCTP has a carbon instead of a sulfur
at the point of steric conflict. The van der Waals radius of
carbon is smaller than that of sulfur, reducing the severity of
the steric clash. In addition, as predicted by this model,
resistance of M184 mutants to the b-L- version of other
nucleoside inhibitors is approximately 50- to 500-fold higher
than resistance to the b-D-enantiomers of the same inhibitors
(42), as is the case for all reported examples, including 3TCTP,
FTCTP, CBVTP (carbovir), d4TTP (stavudine), ddTTP, and
ddCTP (42).
4(S)-(6-Amino-9H-purin-9-yl)tetrahydro-2(S)-furanmetha-
nol (IsoddA) is a structurally unique NRTI stereochemically
similar to b-D-ddI, but with its base transposed from the
natural 19 position to the 29 position (Fig. 1). A single Met to
Val mutation at codon 184 of RT renders HIV-1 resistant to
IsoddA (51). Because of transposition of the base, the ring of
IsoddA is expected to project toward the 184 side chain, in a
way similar to the b-L-nucleoside inhibitors. Hence, the model
FIG. 4. Schematic illustration of proposed steric conflict between
3TCTP and 184I. The van der Waals volume of the side chain of I184
(green) is shown to overlap (red) with the sulfur of the b-L-oxathiolane
ring of the incoming 3TCTP (yellow). A dCTP molecule (green) is
shown superimposed on 3TCTP (white) in a way that maintains the
same base pairing with a modeled template strand and proximity to the
39-OH, but without steric conflict with I184. The model predicts
similar steric hindrance with the two other b-branched amino acids
(Val and Thr). The side chains of these amino acids are shown in an
orientation similar to the I184 observed in our structure. This model
is supported by the reported resistance of M184V and M184T RT to
3TCTP. An analogous model can explain resistance of analogous
mutants of HBV RT to 3TCTP.
FIG. 3. Ribbon diagram of the superimposed polymerase active sites of wild-type HIV-1 RTyDNAyFab and M184I HIV-1 RTyDNAyFab. The
wild-type protein and DNA are shown in gray, the mutant protein in red, and DNA in the mutant RTyDNA complex in yellow.
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can be used to explain resistance of 184 mutants with
b-branched side-chains to IsoddA on the basis of the structural
similarity between IsoddA and the b-L-nucleoside inhibitors.
The model can also explain the structural basis of 3TC
resistance of other polymerases. We have constructed a three-
dimensional model of the HBV active site based on the crystal
structure of the HIV-1 RTyDNA complex and the sequence
homology between HIV-1 RT and HBV polymerase. This
model suggests that, like in HIV-1 RT, mutation of the Met of
the YMDD motif (M552 in HBV) to a b-branched residue (Ile
or Val) would cause steric conflict with the oxathiolane ring of
3TC. However, additional mutations outside the YMDD motif
of the HBV polymerase have been reported to confer 3TC
resistance, suggesting that other interactions may also affect
HBV polymerase sensitivity to 3TCTP (8, 52). Similar to the
HIV-1 and HBV enzymes, simian immunodeficiency virus RT
develops resistance to 3TC through Met to Ile mutation in the
YMDD motif (36), and it was recently reported that the Met
to Thr mutation in the YMDD motif of feline immunodefi-
ciency virus RT confers resistance to oxathiolane nucleosides
(37, 38). Interestingly, MuLV RT, which has a valine as residue
X at the YXDD motif, is naturally resistant to 3TCTP (30).
Possible Role of Template-Primer Repositioning in Resis-
tance to 3TC and Other NRTIs. In the M184I RTyDNA
complex, changes are observed in the position of the template-
primer, along with less pronounced changes at residues such as
L74, D110, Y115, F116, Q151, and D185, but not in the
uncomplexed mutant. When the substrate is a dNTP, these
changes may be the cause of the moderate reductions in
polymerase activity, processivity, and dNTP binding that have
been reported for the mutant enzyme (41–42, 53). M184I
retains the ability to incorporate normal nucleotides in a
reasonably efficient manner (35, 41, 48), suggesting that the
transition state geometry of M184I RT resembles that of the
wild-type enzyme.
It is not clear whether the template-primer shift observed in
the M184IyDNA complex is maintained in the M184IyDNAy
3TCTP ternary complex and to what extent nucleic acid
repositioning contributes to 3TC resistance. A shift in the
position of the primer would likely contribute to a misalign-
ment of 3TCTP at the transition state and a decrease in the
turnover rate of the reaction. Alternatively, shifting the primer
back to the position it occupies in a complex with wild-type RT
may incur an energetic cost that could also affect formation of
the transition state. When a dNTP is the substrate, the effect
of primer shift may contribute to the modest changes in
polymerization rate, processivity, and dNTP binding seen with
the mutant enzyme. When 3TCTP is the incoming substrate,
the primer shift may increase the free energy needed to reach
the transition state and contribute to 3TC resistance.
Low-level resistance to dideoxynucleoside inhibitors
(ddNTPs) has been reported for 184 mutants of HIV-1 RT (2-
to 5-fold) (29, 34, 54). This may be related to the distortions
of the dNTP-binding pocket caused (i) by changes in the
binding of template-primer andyor (ii) by movements of
residues near the dNTP-binding pocket (Y115, F116, Q151,
D110, D185, and L74). Substitution of two of these residues
(L74V or Q151M) (34, 55) causes phenotypic resistance of
HIV-1 RT to ddI and ddC. The 39-hydroxyl of a normal dNTP
substrate makes a hydrogen-bond interaction with the back-
bone NH of Y115 (15); loss of this interaction could alter the
position at which a ddNTP is bound. The loss of this hydrogen
bond could exacerbate the changes at the M184I dNTP-
binding site and result in low-level resistance to ddNTP
inhibitors.
Implications for Drug Design. In conclusion, we have
presented a model that explains resistance to 3TC in HIV-1
and other retroviral RTs and in HBV polymerase. We propose
that high-level resistance to b-L-nucleoside inhibitors (3TC,
FTC) or NRTIs with similar ring orientation (IsoddA) results
from a steric conflict between a b-branched amino acid residue
at the 184 position of HIV-1 RT and the b-L- or similarly
shaped nucleoside ring. Inhibitor molecules designed to have
reduced steric conflict with b-branched amino acids at position
184 should not be excluded as effectively by the M184I and
M184V mutants. Such inhibitors should include 3TC deriva-
tives that contain in place of the sulfur (radius 5 1.80 Å) more
compact atoms such as oxygen (radius 5 1.52 Å) or carbon
(radius 5 1.70 Å for methylene). Alternatively, analogs of 3TC
containing ring system modifications (e.g., unsaturated, acy-
clic, or four-membered) may also have less steric clash than
3TC. These inhibitors would potentially have advantages for
treating AIDS and viruses whose polymerases have similar
active sites, for example hepatitis B.
We thank Aaron Shatkin for useful suggestions on the manuscript,
Pat Clark for help in protein production, and Yu Hsiou, Karen Lentz,
Chris Tantillo, Hemant Yennawar, Wanyi Zhang, and Steve Ealick,
Dan Thiel, and coworkers at Cornell High Energy Synchrotron Source
and Lonny Berman and coworkers at Brookhaven National Light
Source for help with data collection. S.G.S. is supported by a National
Institutes of Health–National Institute of Allergy and Infectious
Diseases National Research Service Award fellowship (AI 09578) and
dedicates his efforts in this work to the memory of George E.
Sarafianos. The research in E.A.’s laboratory has been supported by
National Institutes of Health Grant AI 36144 and the Keck Founda-
tion. S.H.H.’s laboratory is sponsored in part by the National Cancer
Institute, Department of Health and Human Services, under contract
with Advanced BioScience Laboratories and by the National Institutes
of General Medical Sciences.
1. Furman, P. A., Davis, M., Liotta, D. C., Paff, M., Frick, L. W.,
Nelson, D. J., Dornsife, R. E., Wurster, J. A., Wilson, L. J., Fyfe,
J. A., et al. (1992) Antimicrob. Agents Chemother. 36, 2686–2692.
2. Kukhanova, M., Liu, S. H., Mozzherin, D., Lin, T. S., Chu, C. K.
& Cheng, Y. C. (1995) J. Biol. Chem. 270, 23055–23059.
3. Chen, C. H., Vazquez-Padua, M. & Cheng, Y. C. (1991) Mol.
Pharmacol. 39, 625–628.
4. Schinazi, R. F., McMillan, A., Cannon, D., Mathis, R., Lloyd,
R. M., Peck, A., Sommadossi, J. P., St. Clair, M., Wilson, J.,
Furman, P. A., et al. (1992) Antimicrob. Agents Chemother. 36,
2423–2431.
5. Severini, A., Liu, X. Y., Wilson, J. S. & Tyrrell, D. L. J. (1995)
Antimicrob. Agents Chemother. 39, 1430–1435.
6. Maynard, J. E. (1990) Vaccine 8, Suppl., S18–S20.
7. Dienstag, J. L., Perillo, R. P., Schiff, E. R., Bartholomew, M.,
Vicary, C. & Rubin, M. (1995) N. Engl. J. Med. 333, 1657–1661.
8. Chang, C. N., Doong, S. L., Zhou, J. H., Beach, J. W., Jeong, L. S.,
Chu, C. K., Tsai, C. H., Liotta, D., Schinazi, R. F. & Cheng, Y. C.
(1992) J. Biol. Chem. 267, 13938–13942.
9. Allen, M. I., Deslauriers, M., Andrews, C. W., Tipples, G. A.,
Walters, K. A., Tyrrell, D. L. J., Brown, N. & Condreay, L. D.
(1998) Hepatology 27, 1670–1677.
10. Esnouf, R., Ren, J., Ross, R., Jones, Y., Stammers, D. & Stuart,
D. (1995) Nat. Struct. Biol. 2, 303–308.
11. Rodgers, D. W., Gamblin, S. J., Harris, B. A., Ray, S., Culp, J. S.,
Hellmig, B., Woolf, D. J., Debouck, C. & Harrison, S. C. (1995)
Proc. Natl. Acad. Sci. USA 92, 1222–1226.
12. Hsiou, Y., Ding, J., Das, K., Clark, A. D., Jr., Hughes, S. H. &
Arnold, E. (1996) Structure (London) 4, 853–860.
13. Jacobo-Molina, A., Ding, J., Nanni, R. G., Clark, A. D., Jr., Lu,
X., Tantillo, C., Williams, R. L., Kamer, G., Ferris, A. L., Clark,
P., et al. (1993) Proc. Natl. Acad. Sci. USA 90, 6320–6324.
14. Ding, J., Das, K., Hsiou, Y., Sarafianos, S. G., Clark, A. D., Jr.,
Jacobo-Molina, A., Tantillo, C., Hughes, S. H. & Arnold, E.
(1998) J. Mol. Biol. 284, 1095–1111.
15. Huang, H., Chopra, R., Verdine, G. L. & Harrison, S. C. (1998)
Science 282, 1669–1675.
16. Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A. & Steitz,
T. A. (1992) Science 256, 1783–1790.
17. Johnson, M. S., McClure, M. A., Feng, D.-F., Gray, J. &
Doolittle, R. F. (1986) Proc. Natl. Acad. Sci. USA 83, 7648–7652.
18. Larder, B. A., Purifoy, D. J. M., Powell, K. L. & Darby, G. (1987)
Nature (London) 327, 716–717.
Biochemistry: Sarafianos et al. Proc. Natl. Acad. Sci. USA 96 (1999) 10031
19. Doolittle, R. F., Feng, D.-F., Johnson, M. S. & McClure, M. A.
(1989) Q. Rev. Biol. 64, 1–30.
20. Poch, O., Sauvaget, I., Delarue, M. & Tordo, N. (1989) EMBO
J. 8, 3867–3874.
21. Inouye, S. & Inouye, M. (1993) Curr. Opin. Genet. Dev. 3,
713–718.
22. Boyer, P. L., Ferris, A. L., Clark, P., Whitmer, J., Frank, P.,
Tantillo, C., Arnold, E. & Hughes, S. H. (1994) J. Mol. Biol. 243,
472–483.
23. Tantillo, C., Ding, J., Jacobo-Molina, A., Nanni, R. G., Boyer,
P. L., Hughes, S. H., Pauwels, R., Andries, K., Janssen, P. A. J.
& Arnold, E. (1994) J. Mol. Biol. 243, 369–387.
24. Sarafianos, S. G., Pandey, V. N., Kaushik, N. & Modak, M. J.
(1995) Biochemistry 34, 7207–7216.
25. Shirasaka, T., Kavlick, M. F., Ueno, T., Gao, W.-Y., Kojima, E.,
Alcaide, M. L., Chokekijchai, S., Roy, B. M., Arnold, E.,
Yarchoan, R., et al. (1995) Proc. Natl. Acad. Sci. USA 92,
2398–2402.
26. Martin-Hernandez, A., Domingo, E. & Menendez-Arias, L.
(1996) EMBO J. 15, 4434–4442.
27. Sarafianos, S. G., Das, K., Ding, J., Boyer, P. L., Hughes, S, H.
& Arnold, E. (1999) Chem. Biol. 5, 257–264.
28. Boucher, C. A., Cammack, N., Schipper, P., Schuurman, R.,
Rouse, P., Wainberg, M. A. & Cameron, J. M. (1993) Antimicrob.
Agents Chemother. 37, 2231–2234.
29. Gao, Q., Gu, Z., Parniak, M. A., Cameron, J., Cammack, N.,
Boucher, C. & Wainberg, M. A. (1993) Antimicrob. Agents
Chemother. 37, 1390–1392.
30. Schinazi, R. F., Lloyd, R. J. J., Nguyen, M.-H., Cannon, D. L.,
McMillan, N., Ilksoy, N., Chu, C. K., Liotta, D. C., Bazmi, H. Z.
& Mellors, J. W. (1993) Antimicrob. Agents Chemother. 37,
875–881.
31. Schinazi, R. F. (1993) Perspect. Drug Discovery Des. 1, 151–180.
32. Tisdale, M., Kemp, S. D., Parry, N. R. & Larder, B. A. (1993)
Proc. Natl. Acad. Sci. USA 90, 5653–5656.
33. De Clercq, E. (1994) Biochem. Pharmacol. 47, 155–169.
34. Schinazi, R. F., Larder, B. A. & Mellors, J. W. (1997) Int. Antiviral
News 5, 129–142.
35. Keulen, W., Back, N. K. T., Van Wijk, A., Boucher, C. A. B. &
Berkhout, B. (1997) J. Virol. 71, 3346–3350.
36. Cherry, E., Slater, M., Salomon, H., Rud, E. & Wainberg, M. A.
(1997) Antimicrob. Agents Chemother. 41, 2763–2765.
37. Smith, R., Remington, K. M., Lloyd, R. M. J., Schinazi, R. F. &
North, T. W. (1997) J. Virol. 71, 2357–2362.
38. Smith, R. A., Remington, K. M., Preston, B. D., Schinazi, R. F.
& North, T. W. (1998) J. Virol. 72, 2335–2340.
39. Zhu, Y. L., Dutschman, D. E., Liu, S. H., Bridges, E. G. & Cheng,
Y. C. (1998) Antimicrob. Agents Chemother. 42, 1805–1810.
40. Boyer, P. L., Tantillo, C., Jacobo-Molina, A., Nanni, R. G., Ding,
J., Arnold, E. & Hughes, S. H. (1994) Proc. Natl. Acad. Sci. USA
91, 4882–4886.
41. Boyer, P. L. & Hughes, S. H. (1995) Antimicrob. Agents Che-
mother. 39, 1624–1628.
42. Wilson, J. E., Aulabaugh, A., Caligan, B., McPherson, S., Wake-
field, J. K., Jablonski, S., Morrow, C. D., Reardon, J. E. &
Furman, P. A. (1996) J. Biol. Chem. 271, 13656–13662.
43. Krebs, R., Immendorfer, U., Thrall, S. H., Wo¨hrl, B. M. &
Goody, R. S. (1997) Biochemistry 36, 10292–10300.
44. Brunger, A. T. (1996) X-PLOR Manual Version 3.8: A System for
X-Ray Crystallography and NMR.
45. Jacques, P. S., Wo¨hrl, B. M., Ottmann, M., Darlix, J. L. & Le
Grice, S. F. J. (1994) J. Biol. Chem. 269, 26472–26478.
46. Ghosh, M., Jacques, P. S., Rodgers, D. R., Ottman, M., Darlix,
J.-L. & Le Grice, S. F. (1996) Biochemistry 35, 8553–8562.
47. Wo¨hrl, B. M., Krebs, R., Thrall, S. H., Le Grice, S. F. J., Scheidig,
A. J. & Goody, R. S. (1997) J. Biol. Chem. 272, 17581–17587.
48. Back, N. K. T., Nijhuis, M., Keulen, W., Boucher, C. A. B., Oude
Essink, B. B., van Kuilenburg, A. B. P., van Gennip, A. H. &
Berkhout, B. (1996) EMBO J. 15, 4040–4049.
49. Faraj, A., Agrofoglio, L. A., Wakefield, J. K., McPherson, S.,
Morrow, C. D., Gosselin, G., Mathe, C., Imbach, J., Schinazi,
R. F. & Sommadossi, J. P. (1994) Antimicrob. Agents Chemother.
38, 2300–2305.
50. Van Draanen, N., Tisdale, M., Parry, N. R., Jansen, R., Dornsife,
R. E., Tuttle, J. V., Averett, D. R. & Koszalka, G. W. (1994)
Antimicrob. Agents Chemother. 38, 868–871.
51. Nair, V., St. Clair, M., Reardon, J., Krasny, H., Hazen, R., Paff,
M., Boone, L., Tisdale, M., Najera, I. & Dornsife, R. E. (1995)
Antimicrob. Agents Chemother. 39, 1993–1999.
52. Fu, L. & Cheng, Y. C. (1998) Biochem. Pharmacol. 55, 1567–
1572.
53. Pandey, V. N., Kaushik, N., Rege, N., Sarafianos, S. G., Yadav,
N. S. & Modak, M. J. (1996) Biochemistry 35, 2168–2179.
54. St. Clair, M. H., Martin, J. L., Tudor-Williams, G., Bach, M. C.,
Vavro, C. L., King, D. M., Kellam, P., Kemp, S. D. & Larder,
B. A. (1991) Science 253, 1557–1559.
55. Ueno, T. & Mitsuya, H. (1997) Biochemistry 36, 1092–1099.
10032 Biochemistry: Sarafianos et al. Proc. Natl. Acad. Sci. USA 96 (1999)
